TW587936B - Pharmaceutical composition containing proton pump inhibitors - Google Patents
Pharmaceutical composition containing proton pump inhibitors Download PDFInfo
- Publication number
- TW587936B TW587936B TW089103033A TW89103033A TW587936B TW 587936 B TW587936 B TW 587936B TW 089103033 A TW089103033 A TW 089103033A TW 89103033 A TW89103033 A TW 89103033A TW 587936 B TW587936 B TW 587936B
- Authority
- TW
- Taiwan
- Prior art keywords
- scope
- patent application
- item
- composition according
- propylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
A7 —----- -B7_________ 五、發明說明(1 ) 發明概要 本發明係有關一種經改良的口服奥米咪唑糊劑調配物。 發明背景 奥米咪唑係一種有抑制H+K七ATp酶作用之胃酸分泌強效 抑制劑,該酶涉及側膜細胞產生氫離子的最終步驟,且奥 米咪唑已用於治療與胃酸有關的疾病,如人類的胃及十二 ^腸/貝瘍。消化道潰瘍在某些動物亦常見,特別是馬匹。 雖然馬匹胃-十二腸潰瘍的病因學尚未確立,但似乎在某 些狀況下壓力扮演重要角色。 奥米咪唑對酸極不安定且因而其口服調配物有腸溶衣。 有腸/合衣的凋配物造價筇貴且費時,並需要精細的技術及 $又備。有腸溶衣的調配物的另一個缺點是易受潮。 W0 94/25070揭示含有質子幫浦抑制劑且有腸溶衣的乾 燥顆粒形式口服組合物經與膠化劑混合,然後該混合物可 在扠藥㈤製成似糊劑之凝膠。因此該組合物需要塗覆腸溶 衣,而伴布上述與此碉配物有關的缺點。此外,因爲這類 /然凝膠在室溫下長期儲存期間不安定,故其不能以現成調 配物裳迻及販售,而是必須在投藥時臨時製備,使其不便 於利用。 u S專利5,708,017説明了質子.幫浦抑制劑之糊劑調配 物,其包括質子·幫浦抑制劑、增稠劑、鹼化劑及疏水的 油性液態載體。 發明之詳細説明 本發明k供一種經改良的奥米咪唑糊劑調配物,其包括· -4 - 本纸張尺度適用中國國家標準(CNS)A4 --- (請先閱讀背面之注意事項再填寫本頁) ---- 訂--- 經濟部智慧財產局員工消費合作社印制π 587936 A7 137 五、發明說明(2 (a)約1%至60% w/w之奥米味哇, (b )約0.1 %至2% w/w之二至四種驗化劑, (c )約1 %至3 % w/w之增稠劑,及 (d)約30%至95% w/w之疏水的油性液態載體,包括 (i) 植物油及 (i i )中鏈脂肪酸之三酸甘油酯或中鏈脂肪酸之丙 二醇二酯。 奥米咪唑係經揭示於US專利4,255,432。奥米咪唑在本 發明中之含量並非特別關鍵性,只要該藥產品保持爲半固 態製劑;一般可耐受高達約6〇% w/w之奧米咪唑。奧米咪 唑的含量較宜約爲或低於50% w/w,且更宜約自3 〇至4〇% w/w ° 合適的鹼化劑是如醫藥上可接受的胺鹼,如單乙醇胺、 二乙醇胺、三乙醇胺或羧酸之鹽類如乙酸鈉、檸檬酸鈉、 花楸酸鉀、硬脂酸鈉等等。最好鹼化劑之一是花楸酸鉀, 且一或兩種鹼化劑可選自胺鹼如單乙醇胺及一個羧酸鹽如 硬脂酸鈉。該驗化劑之含量係足以提供非酸性的環境給對 酸不安定的奥米咪唑;典型地,該鹼化劑之總含量爲自 0 . 1至2% w/w且最好約自!至! 5% w/w。 該增稍劑可爲任何μ上可接受的非水溶性或部分非水 溶性増稠劑;實例包括二氧切、臘如海賴或經氯化的 海捏油、石壞、絲硬脂醇等等。較宜的疏水性増稠劑係經 氫化的海狸油。增稠劑的含量係約最終組合物之〇 5❶〆〇至 1 0% w/w ;最好,其約1至2% w/w。 (請先閱讀背面之注意事項再填寫本頁) ---- — l· — — 訂- 經濟部智慧財產局員工消費合作社印則衣 5- 587936 A7 B7 五、發明說明( 3 經濟部智慧財產局員工消費合作社印製 該疏水的油性液態載體包含(i )植物油及(i i )中鏈脂肪 酸之三酸甘油酯或中鏈脂肪酸之丙二醇二酯。植物油的實 例包括杏仁油、棉籽油、橄欖油、花生油、葵花油、芝麻 油及大豆油。較宜的植物油係芝麻油。中鏈脂肪酸係凡碳 鏈長自八至十二之脂肪酸;最好該脂肪酸爲飽和脂肪酸。 較宜的三酸甘油酯及丙二醇二酯係癸酸/辛酸三酸甘油酯 及丙二醇癸酸酯/辛酸酯(亦稱爲丙二醇辛酸酯癸酸酯)。 癸酸/辛酸三酸甘油酯及丙二醇癸酸酯/辛酸酯係可商購之 產品如凡以麥格利奥(Miglyol)®商品名(休斯亞美利加股份 有限公司,紐澤西)銷售者。更宜的疏水油性液態載體包 含芝麻油及丙二醇癸酸鹽/辛酸酯(如麥格利奥⑧84〇)。該 疏水性的載體含量係約3 0 %至95% w/w,取決於糊劑中其 他賦形劑的含量。最好該疏水性的載體含量約5 〇至8〇% w/w。在該疏水性的載體中植物油對三酸甘油酯之比例範 圍約自1 : 3至5 : 1 ;最好約自1 ·;[至2 : 1。 本發明之組合物可包括其他常用於人類及家畜藥物之調 配物的成分。可加入例如,香料如焦糖、胡蘿笥、蘋果、 肉桂及臘腸香料;呈色劑如氧化鐵、二氧化鈦、鋁沉澱色 料:甜味劑如糖、糖精鈉;防腐劑如對氧苯甲酸;抗氧化 劑如BHT、BHA ;分散劑如硬脂酸鈣;及黏度調整劑如白 臘或合成臘如甘油基參二十二碳酸鹽(tribehenate )、甘油 基三肉且寇酸酯、經氫化的可可甘油酯。 本發明組合物之製備可分散粉末形式之奧米咪唑於含除 增稠劑以外的任何其他賦形劑之疏水液態載體中。然後加 -6- 表纸狀度適用帽國家標^公楚) (請先閱讀背面之注意事項再填寫本頁) ---- ϋ l· 1 n · =口 經濟部智慧財產局員工消費合作社印制代 587936 A7 _____ B7 五、發明說明(4 ) 增稠劑至該混合物中並攪拌以達需要之黏稠度。本發明組 合物之製備亦可分散賦形劑於疏水的油性液態載體中,接 著添加增稠劑’且若有需要可額外加入植物油以達需要之 黏稠度;於產生之混合物中加入粉末形式的奥米咪唑且充 分混合整個混合物以分散奥米咪唑。因此取得之糊劑調配 物可用以填充配藥注射筒,其可直接用以投與有效藥給需 要治療之動物。 本發明之奥米咪唑糊劑調配物具有超越以往奥米咪唑糊 劑調配物之經改良特性。本發明之調配物具有較好的物理 及化學安定性表現形式,且提供較高的藥物生物效性。 本發明之組合物係對治療人類及動物消化道潰瘍疾病有 用。在動物其可用於經口遞送奥米咪唑於系統性效果。該 組合物也可用以遞送奥米咪唑給吞嚥固態劑型如有腸溶衣 的錠劑及膠囊有困難的人。該組合物可直接投至需要抗潰 瘍療法的動物口中,如馬匹;最好利用糊劑配藥注射筒幫 助投藥。此糊劑之黏調度需足使其一旦經置於動物舌背上 就不易滴出或被排出。該糊劑特別不含氣泡以增進下藥之 正確性。此調配物之另一優點是可投予個別之劑量。 該組合物的投藥量可根據所治療之特姝動物種類、該疾 病的嚴重性、該生病動物之生理狀況及其他因素變化。凡 熟稔治療潰瘍之技藝的醫師或售醫可輕易決定對於接受治 療之特定宿主適當之劑量。通常,可用之劑量範園係約自 0.2 mg/kg 至 20 mg/kg。 以下實例係提供更完整的闡明本發明,且不應被以任何 本纸張&度適用中國國家標準(CNS)A4規格(21〇 χ 297"^·^—~----------- (請先閱讀背面之注意事項再填寫本頁) ---- 587936 A7 B7 五、發明說明(5) 方式解釋爲本發明範圍之限制。 實例成分 奥米咪唑鹼 花楸酸神 硬脂酸鈉 硬脂酸飼 單乙醇胺 黃氧化鐵 肉桂油 經氫化的海狸油 丙二醇辛酸酯癸酸酯 芝麻油 互全率w/w 37.0 0.20 0.10 1.0 0.10 0.20 0.30 1.25 25.0qs (請先閱讀背面之注意事項再填寫本頁) ---- 經濟部智慧財產局員工消費合作社印制π 加花楸酸鉀(0.50 kg)、硬脂酸鈣(2·50 kg)、硬脂酸納 (0·25 kg)及黃氧化鐵(〇.50 kg)至二重錐形混合機並混合成 分散粉末。使產生之粉末通過6 0篩孔之篩網並以高速研 磨。收集該經研磨之粉末預拌物於聚乙烯袋中以用於糊劑 之製造。 在一合適大小之垂直螺旋半固態糊劑攪拌器中加入丙二 醇辛酸S旨癸酸醋(62.5 kg)及芝麻油(37.5 kg)。若有需要, 調整該液態混合物之溫度至約低於25°C,並打開攪掉螺 旋。打開糰塊破碎機同時加該經研磨之粉末預拌物、單乙 醇胺(0.25 kg)、及肉桂油(0.75 kg)至該攪拌器。然後,力口 經氫化的海狸油(3 · 13 kg )至該攪拌器,並攪拌至該產品溫 -8- 本纸張尺度遠用中國國家標準(CNS)A4規格(210 X 297公釐) -----訂 ---- 587936 A7 B7 五、發明說明(6 ) 度達50 ±5°C。停止該攪拌螺旋及該糰塊破碎機並靜置該 批容器中的内容物30土5分鐘以確保完成凝膠過程。^ μ 打開冷卻水同時加剩餘之芝麻油(49 6 kg)至攪拌器。打 開攪拌螺旋及糰塊破碎機約二分鐘以分散原料炊後停止。 將奥米咪❹末(92.5kg)分爲8_10份加至攪拌器;在每加 二 =打開該攪拌器一段足以濕潤大部分之粉末的時間 ==力:入下—份。在加入所有的奥米備,再繼 碎乂完全分散奥米咪峻;然後打開該糰塊破 檀掉1〇分鐘以確保完全之均質性。將產生 <糊劑包裝於針筒中。 (請先閱讀背面之注意事項再填寫本頁) ----- i^i ϋ J ,• — ΜΜ βΙΗΜ ΜΒΜ MM I I · ♦ 經濟部智慧財產局員工消費合作社印製
Claims (1)
- 587936 第089103033號專利申請案 中文申請專利範圍替換本(92年4月) A8 B8 C8 D8 六、申請專利範圍 I# i φ. ν .: ^ I 衣年月曰 補充 1· 一種口服醫藥組合物,其包括: (a) 約1 %至60% w/w之奥米咪唑’ (b )約〇 · 1 %至2 % w / w之二至四種鹼化劑’ (c )約1 %至3 % w / w之增桐劑’及 (d )疏水性的油性液態媒劑包括 (i) 植物油及 (Π)中鏈脂肪酸之三酸甘油酯或中鏈脂肪酸之丙 二醇二酯。 2·根據申請專利範圍第1項之組合物,其中該增稠劑係經 氮化的海捏油。 3·根據申請專利範圍第1項之組合物,其中該疏水性的液 態載體包含丙二醇癸酸鹽/辛酸酯及植物油。 4·根據申請專利範圍第丨項之組合物,其中該疏水性的液 態載體包含芝麻油及中鏈脂肪酸之三酸甘油酯或中鏈脂 肪酸之丙二醇二酯。 5.根據申請專利範圍第1項之組合物,其中該疏水性的液 態載體包含丙二醇癸酸鹽/辛酸酯及芝麻油。 6·根據申請專利範圍第1項之組合物,其中鹼化劑之一為 花楸酸4甲。 7_根據申請專利範圍第1項之組合物,其中該鹼化劑係花 楸酸鉀、硬脂酸鈉及單乙醇胺。 8·根據申請專利範圍第1項之組合物,其中奥米咪唑含量 約為3 0至40% w/w。 9·根據申請專利範圍第1項之組合物,其中該鹼化劑總含 本紙張尺度國家標準(0^八4規格(2ΐο χ 297公爱) 587936 8 8 8 8 A BCD 々、申請專利範圍 量係自約1至1.5% w/w。 10. 稂據申請專利範圍第1項之組合物,其中該疏水性的油 性液態媒劑含量約為30%至90% w/w。 11. 根據申請專利範圍第1項之組合物,其中該疏水性的油 性液態媒劑含量約為50%至80% w/w。 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12125399P | 1999-02-23 | 1999-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW587936B true TW587936B (en) | 2004-05-21 |
Family
ID=22395498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW089103033A TW587936B (en) | 1999-02-23 | 2000-02-22 | Pharmaceutical composition containing proton pump inhibitors |
Country Status (31)
Country | Link |
---|---|
US (1) | US6316481B1 (zh) |
EP (1) | EP1156806B1 (zh) |
JP (1) | JP2002537337A (zh) |
KR (1) | KR100701448B1 (zh) |
CN (1) | CN1227009C (zh) |
AR (1) | AR029615A1 (zh) |
AT (1) | ATE263562T1 (zh) |
AU (1) | AU771061B2 (zh) |
BG (1) | BG65291B1 (zh) |
BR (1) | BR0008403A (zh) |
CA (1) | CA2362932C (zh) |
CO (1) | CO5140102A1 (zh) |
CZ (1) | CZ301647B6 (zh) |
DE (1) | DE60009675T2 (zh) |
DK (1) | DK1156806T3 (zh) |
EA (1) | EA004683B1 (zh) |
ES (1) | ES2216870T3 (zh) |
HK (1) | HK1041650A1 (zh) |
HR (1) | HRP20010615B1 (zh) |
HU (1) | HU228181B1 (zh) |
IL (1) | IL144131A0 (zh) |
ME (1) | ME00864B (zh) |
NO (1) | NO328863B1 (zh) |
NZ (1) | NZ512771A (zh) |
PL (1) | PL195783B1 (zh) |
PT (1) | PT1156806E (zh) |
RS (1) | RS50023B (zh) |
SK (1) | SK286371B6 (zh) |
TW (1) | TW587936B (zh) |
WO (1) | WO2000050038A1 (zh) |
ZA (1) | ZA200106104B (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
ES2345873T3 (es) * | 2000-05-30 | 2010-10-05 | Merial Limited | Composiciones para la prevencion de ulceras en caballos. |
SI1341524T1 (sl) | 2000-12-07 | 2012-02-29 | Nycomed Gmbh | Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino |
KR20030059318A (ko) | 2000-12-07 | 2003-07-07 | 알타나 파마 아게 | 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제 |
DE10061135C1 (de) * | 2000-12-07 | 2002-11-07 | Byk Gulden Lomberg Chem Fab | Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff |
CA2493618A1 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
GB2394895A (en) * | 2002-11-06 | 2004-05-12 | Cipla Ltd | Proton pump inhibitor composition in paste form |
WO2005000269A1 (en) * | 2003-06-26 | 2005-01-06 | Cipla Limited | Pharmaceutical formulations comprising a proton pump inhibitor |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2006026829A1 (en) * | 2004-09-09 | 2006-03-16 | Metelli Pty Ltd | Stable paste composition of enteric coated acid labile active agent and use thereof |
CN101500553B (zh) * | 2006-07-25 | 2012-04-18 | 维克塔有限公司 | 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法 |
AU2008215659B2 (en) | 2007-02-16 | 2012-11-01 | Aska Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising microparticle oily suspension |
EP2456439A4 (en) * | 2009-07-20 | 2012-12-26 | Vetegen Llc | STABLE PHARMACEUTICAL OMEPRAZOLE FORMULATION FOR ORAL ADMINISTRATION |
US8722636B2 (en) | 2011-01-31 | 2014-05-13 | New Market Pharmaceuticals, LLC | Animal treatments |
EP3791866A1 (en) | 2012-05-02 | 2021-03-17 | NewMarket Pharmaceuticals LLC | Pharmaceutical compositions for direct systemic introduction |
US10064849B2 (en) | 2012-05-02 | 2018-09-04 | New Market Pharmaceuticals | Pharmaceutical compositions for direct systemic introduction |
GB2524351B (en) * | 2013-10-18 | 2016-12-14 | Norbrook Lab Ltd | Proton Pump Inhibitor Paste Compositions |
EP3057571B1 (en) * | 2013-10-18 | 2019-03-06 | Norbrook Laboratories Limited | Proton pump inhibitor paste compositions |
WO2017096426A1 (en) | 2015-12-08 | 2017-06-15 | Luoda Pharma Pty Limited | Methods and compositions for treating gastric ulcers |
WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CA3033065A1 (en) * | 2016-08-11 | 2018-02-15 | Adamis Pharmaceuticals Corporation | Drug compositions |
EP3720844A4 (en) | 2017-12-08 | 2021-08-11 | Adamis Pharmaceuticals Corporation | MEDICINAL COMPOSITIONS |
ES2723873B1 (es) * | 2018-03-01 | 2020-05-13 | Hernan Ma Carmen Batanero | Medicamento combinado con omeprazol y vitamina B12 |
CN112972481A (zh) * | 2021-03-18 | 2021-06-18 | 华农(肇庆)生物产业技术研究院有限公司 | 药物组合物及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4255432A (en) | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
DK130287D0 (da) | 1987-03-13 | 1987-03-13 | Benzon As Alfred | Oralt praeparat |
SE9301489D0 (sv) | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
-
2000
- 2000-02-18 ES ES00911862T patent/ES2216870T3/es not_active Expired - Lifetime
- 2000-02-18 SK SK1206-2001A patent/SK286371B6/sk not_active IP Right Cessation
- 2000-02-18 CZ CZ20013058A patent/CZ301647B6/cs not_active IP Right Cessation
- 2000-02-18 BR BR0008403-4A patent/BR0008403A/pt not_active Application Discontinuation
- 2000-02-18 AT AT00911862T patent/ATE263562T1/de active
- 2000-02-18 EA EA200100905A patent/EA004683B1/ru not_active IP Right Cessation
- 2000-02-18 DK DK00911862T patent/DK1156806T3/da active
- 2000-02-18 ME MEP-2001-504A patent/ME00864B/me unknown
- 2000-02-18 AU AU33687/00A patent/AU771061B2/en not_active Expired
- 2000-02-18 CN CNB00804029XA patent/CN1227009C/zh not_active Expired - Lifetime
- 2000-02-18 RS YUP-504/01A patent/RS50023B/sr unknown
- 2000-02-18 JP JP2000600649A patent/JP2002537337A/ja active Pending
- 2000-02-18 CA CA2362932A patent/CA2362932C/en not_active Expired - Lifetime
- 2000-02-18 EP EP00911862A patent/EP1156806B1/en not_active Expired - Lifetime
- 2000-02-18 PT PT00911862T patent/PT1156806E/pt unknown
- 2000-02-18 DE DE60009675T patent/DE60009675T2/de not_active Expired - Lifetime
- 2000-02-18 IL IL14413100A patent/IL144131A0/xx not_active IP Right Cessation
- 2000-02-18 HU HU0200325A patent/HU228181B1/hu unknown
- 2000-02-18 KR KR1020017010623A patent/KR100701448B1/ko active IP Right Grant
- 2000-02-18 NZ NZ512771A patent/NZ512771A/xx not_active IP Right Cessation
- 2000-02-18 PL PL00350729A patent/PL195783B1/pl unknown
- 2000-02-18 WO PCT/US2000/004170 patent/WO2000050038A1/en active IP Right Grant
- 2000-02-22 US US09/510,312 patent/US6316481B1/en not_active Expired - Lifetime
- 2000-02-22 TW TW089103033A patent/TW587936B/zh not_active IP Right Cessation
- 2000-02-22 CO CO00012143A patent/CO5140102A1/es unknown
- 2000-02-22 AR ARP000100749A patent/AR029615A1/es active IP Right Grant
-
2001
- 2001-07-25 ZA ZA200106104A patent/ZA200106104B/xx unknown
- 2001-07-30 BG BG105754A patent/BG65291B1/bg unknown
- 2001-08-22 NO NO20014074A patent/NO328863B1/no not_active IP Right Cessation
- 2001-08-23 HR HR20010615A patent/HRP20010615B1/xx not_active IP Right Cessation
-
2002
- 2002-05-07 HK HK02103435A patent/HK1041650A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW587936B (en) | Pharmaceutical composition containing proton pump inhibitors | |
JP4603631B2 (ja) | プロトンポンプ阻害剤を含有する医薬組成物 | |
TW492876B (en) | New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture | |
JP2000514406A (ja) | アルギン酸から成る経口投与製剤用腸溶性被膜 | |
DE3346525A1 (de) | Pharmazeutische zubereitung mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich | |
US20130251815A1 (en) | Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles | |
JP3224379B1 (ja) | 8−クロロ−6,11−ジヒドロ−11−(4−ピペリジリデン)−5H−ベンゾ[5,6]シクロヘプタ[1,2−b]ピリジンの経口用組成物 | |
EP0263493A2 (de) | Pharmazeutische Präparate zur verbesserten gastrointestinalen Resorption | |
CN102579403B (zh) | 盐酸度洛西汀药物组合物 | |
EP0093497A2 (en) | Anthelmintic treatment | |
WO2018222164A9 (en) | USE OF HERB-BASED PREPARATION CONTAINING POUPINE OIL CONTAINING POULTRY OIL IN THE TREATMENT OF BPH | |
GB2394895A (en) | Proton pump inhibitor composition in paste form | |
US20050175686A1 (en) | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule | |
MXPA01008525A (en) | Pharmaceutical composition containing proton pump inhibitors | |
GB2614129A (en) | Chewable semi-solid milk-based drug delivery platform and method for the preparation of milk-based drug compositions and its use | |
RU2246297C2 (ru) | Желатиновые капсулы "гастробиол-цд" на основе клатратов концентрата облепихового масла, обладающие противоязвенным действием | |
WO2018222163A2 (en) | Use of an herbal formula containing pumpkin seed oil in the treatment of overactive bladder and urinary incontinence of the lower urinary system symptoms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |